KPI 1 ‚Äî Percentage of pharmaceutical manufacturing facilities inspected for GMP as per plan

Maturity Level: 3
Type: Output
Definition: Measures how well the regulator executes its annual/quarterly GMP inspection plan.

Formula:

Numerator: Number of pharmaceutical manufacturing facilities inspected as per the plan

Denominator: Total number of facilities planned for inspection

Calculation: (N √∑ D) √ó 100

Unit: %

Reporting Frequency: Quarterly

Disaggregations:

On-site domestic inspections

On-site foreign inspections

Joint on-site foreign inspections (reliance)

Notes:

Remote/desk-based reviews are not counted here (they fall under KPI 3).

EFDA and TMDA plan to inspect all domestic facilities annually.

Alignment:

Harmonized for TMDA, EFDA, Rwanda FDA

Uganda NDA IRIMS does not support planning yet (future inclusion)

üîπ KPI 2 ‚Äî Percentage of complaint-triggered GMP inspections conducted

Maturity Level: 3
Type: Process
Definition: Measures responsiveness to complaints requiring GMP investigations.

Formula:

Numerator: Number of complaint-triggered GMP inspections conducted

Denominator: Total number of complaints requiring GMP inspection

Calculation: (N √∑ D) √ó 100

Unit: %

Frequency: Quarterly

Disaggregations:

Domestic inspections

Foreign inspections (any mode)

Notes:

Ad-hoc indicator; cannot be planned in advance.

Important for public confidence.

Alignment:

TMDA, EFDA, Rwanda FDA ‚Äî aligned

Uganda NDA ‚Äî will not report

üîπ KPI 3 ‚Äî Percentage of GMP on-site inspections waived

Maturity Level: 3
Type: Process
Definition: Measures the use of risk-based and reliance mechanisms to waive on-site inspections.

Formula:

Numerator: Facilities where on-site inspection was waived (remote/desk review done instead)

Denominator: Total GMP inspections completed (physical or remote)

Calculation: (N √∑ D) √ó 100

Unit: %

Frequency: Quarterly

Notes:

An inspection is ‚Äúcompleted‚Äù when an official decision is communicated.

Only remote/desk inspections are counted in numerator.

Alignment:

Fully harmonized across TMDA, EFDA, Rwanda FDA, Uganda NDA

üîπ KPI 4 ‚Äî Percentage of facilities compliant with GMP requirements

Maturity Level: 3
Type: Outcome
Definition: Measures extent of GMP compliance across inspected facilities.

Formula:

Numerator: Number of facilities compliant with GMP requirements

Denominator: Total number of facilities inspected

Calculation: (N √∑ D) √ó 100

Unit: %

Frequency: Annual

Disaggregations:

On-site domestic

On-site foreign

Joint on-site foreign

Remote/desk-based inspections

Alignment:

Harmonized across TMDA, EFDA, Rwanda FDA, Uganda NDA

üîπ KPI 5 ‚Äî Percentage of final CAPA decisions issued within a specified timeline

Maturity Level: 3
Type: Process
Definition: Measures efficiency in evaluating and concluding CAPA responses from manufacturers.

Formula:

Numerator: Final CAPA decisions issued within timeline

Denominator: Total CAPA responses received

Calculation: (N √∑ D) √ó 100

Unit: %

Frequency: Quarterly

Disaggregations:

Direct inspections (domestic + foreign)

Joint inspections (reliance, REC-led)

Notes:

‚ÄúWaiting time‚Äù for applicants is excluded.

Requires integration with EAC systems for reliance reporting.

Alignment:

Fully harmonized across all four NRAs

üîπ KPI 6 ‚Äî Percentage of GMP inspection applications completed within the set timeline

Maturity Level: 3
Type: Process
Definition: Measures efficiency of processing GMP applications end-to-end.

Formula:

Numerator: Applications completed within NRA SLA timeline

Denominator: Total GMP inspection applications received

Calculation: (N √∑ D) √ó 100

Unit: %

Frequency: Quarterly

Disaggregations:

Domestic applicants

Foreign (direct review)

Foreign (reliance-based review)

Stop-clock rules:

Clock starts after payment

TMDA, EFDA, UNDA: payment after screening

Rwanda FDA: payment before screening

Clock stops when final decision issued

Alignment:

Harmonized across all NRAs

üîπ KPI 7 ‚Äî Average turnaround time to complete GMP applications

Maturity Level: 3
Type: Process
Definition: Average number of days NRAs take to complete GMP inspection applications.

Formula:

Numerator: Sum of processing days for all applications completed

Denominator: Number of applications completed

Calculation: N √∑ D

Unit: Days

Frequency: Quarterly

Disaggregations:

On-site domestic

On-site foreign

Joint on-site foreign

EFDA additionally measures document review for reference authority waivers

Notes:

Applicant waiting time is excluded.

‚ÄúFirst decision‚Äù counts (compliant / non-compliant / CAPA required).

Alignment:

Harmonized across TMDA, EFDA, Rwanda FDA, Uganda NDA

üîπ KPI 8 ‚Äî Median turnaround time to complete GMP inspection applications

Maturity Level: 3
Type: Process
Definition: Median number of days required to process GMP inspections.

Formula:

Arrange all completion times in order

If odd: median is middle value

If even: median is average of two middle values

Unit: Days

Frequency: Annual

Notes:

Measured from payment to first decision (excluding applicant time).

Can be reported manually until systems improve.

Alignment:

Harmonized for TMDA, Rwanda FDA

EFDA and UNDA will adopt later

üîπ KPI 9 ‚Äî Percentage of GMP inspection reports published within a specified timeline

Maturity Level: 4
Type: Output
Definition: Tracks transparency and timely publication of GMP inspection outcomes.

Formula:

Numerator: Inspection reports published within timeline

Denominator: Total inspections completed

Calculation: (N √∑ D) √ó 100

Unit: %

Frequency: Annual

Disaggregations:

On-site domestic

On-site foreign

Joint inspections

Remote/desk-based

EFDA also includes document review results for reliance-based waivers

Notes:

TMDA publishes only reports deemed ‚Äúpublic interest‚Äù according to internal criteria

UNDA requires SOP development to manage confidentiality and publication

Alignment:

Harmonized for TMDA, EFDA, Rwanda FDA

Uganda NDA ‚Äî future adoption